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Abstract
Background: Microorganisms causing community-acquired pneumonia (CAP) can be categorised into viral, typical
and atypical (Legionella species, Coxiella burnetii, Mycoplasma pneumoniae, and Chlamydia species). Extensive
microbiological testing to identify the causative microorganism is not standardly recommended, and empiric
treatment does not always cover atypical pathogens. In order to optimize epidemiologic knowledge of CAP and
to improve empiric antibiotic choice, we investigated whether atypical microorganisms are associated with a particular
season or with the patient characteristics age, gender, or chronic obstructive pulmonary disease (COPD).
Methods: A data-analysis was performed on databases from four prospective studies, which all included adult patients
hospitalised with CAP in the Netherlands (N = 980). All studies performed extensive microbiological testing.
Results: A main causative agent was identified in 565/980 (57.7 %) patients. Of these, 117 (20.7 %) were atypical
microorganisms. This percentage was 40.4 % (57/141) during the non-respiratory season (week 20 to week 39,
early May to early October), and 67.2 % (41/61) for patients under the age of 60 during this season. Factors that
were associated with atypical causative agents were: CAP acquired in the non-respiratory season (odds ratio (OR)
4.3, 95 % CI 2.68–6.84), age <60 year (OR 2.9, 95 % CI 1.83–4.66), male gender (OR 1.7, 95 % CI 1.06–2.71) and absence
of COPD (OR 0.2, 95 % CI 0.12–0.52).
Conclusions: Atypical causative agents in CAP are associated with respectively non-respiratory season, age <60 years,
male gender and absence of COPD. Therefore, to maximise its yield, extensive microbiological testing should be
considered in patients <60 years old who are admitted with CAP from early May to early October.
Trial registration: NCT00471640, NCT00170196 (numbers of original studies).
Keywords: Aetiology, Atypical pathogens, Community-acquired pneumonia, Demography, Pneumonia
* Correspondence: s.spoorenberg@antoniusziekenhuis.nl
VM Raeven and SMC Spoorenberg are shared first authors.
†Equal contributors
1Department of Internal Medicine, St Antonius Hospital, Nieuwegein, The
Netherlands
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Raeven et al. BMC Infectious Diseases  (2016) 16:299 
DOI 10.1186/s12879-016-1641-9
Background
Microorganisms causing community-acquired pneumonia
(CAP) can be categorised into viral, typical and atypical
microorganisms. Atypical microorganisms are Legionella
species, Coxiella (C.) burnetii (Q-fever), Mycoplasma (M.)
pneumoniae, and Chlamydia species. In clinical practice,
the causative microorganism often remains unidentified
since microbiological testing is not standardly performed.
However, in patients with low to moderately severe CAP,
treatment of first choice allegedly does not cover atypical
causative microorganisms [1–3]. To start a pathogen-
directed treatment, it is important to define specific
conditions associated with an increased risk for atypical
pathogens.
Cases of CAP are seen throughout the year, but overall
incidence rises during winter months [4]. This is due to
certain aetiological agents that show seasonal variation:
Streptococcus (S.) pneumoniae, Haemophilus influenzae
and respiratory viruses occur mainly during winter sea-
son [4, 5]. Of atypical microorganisms, only Legionella
(L.) species and C. burnetii show seasonal variation, in-
creasing during summer and during early spring in the
lambing season, respectively [6–8]. Numbers of cases of
M. pneumoniae increase during wintertime, but the inci-
dence is relatively high during summer as well.
Concerning age, incidence of CAP is highest in young
children and adults above 65 years old [9, 10]. S. pneu-
moniae is the leading causative agent in all age groups.
Some atypical pathogens show an atypical age distribution.
Cases of L. pneumophila are most commonly seen in pa-
tients aged 35 to 50 years old, psittacosis has an increased
incidence in patients aged 35 to 55, and C. burnetii occurs
most in men between 30 and 69 years old [11–13].
Furthermore, patients with chronic obstructive pul-
monary disease (COPD) or positive smoking status differ
in aetiology of CAP [14, 15]. Consequently, there could
be a positive or negative association with these condi-
tions and the prevalence of atypical pathogens.
Microbiological testing can be used to identify the causa-
tive microorganism and to distinguish between typical and
atypical microorganisms [16]. However, guidelines do not
recommend microbiological testing for patients with low
to moderately severe CAP, and therefore antibiotic treat-
ment of CAP is usually empirical [1–3]. There is no world-
wide consensus on antibiotic management for CAP. The
Dutch Working Party on Antibiotic Policy (SWAB) and
National Institute for Health and Care Excellence (NICE)
guideline recommend amoxicillin as first-choice treatment
for hospitalised patients with CAP of low- to moderate
severity (pneumonia severity index (PSI) classes 1–4 or
CURB-65 score 0–2) and combination with a macrolide or
quinolone in case of severe CAP (PSI class 5 or CURB-65
score > 2) [2, 3]. The British Thoracic Society (BTS) guide-
line recommends amoxicillin with macrolide combination
therapy in case of moderate to severe CAP [1]. Global dif-
ferences in preferred antibiotic management can partially
be explained by variations in pneumococcal resistance rate
between geographical regions and countries [17]. Since S.
pneumoniae is the leading cause of CAP, the initial therapy
should at least cover this microorganism. Nevertheless,
beta-lactam antibiotics do not cover atypical microorgan-
isms, leaving these pathogens theoretically uncovered by
first-choice treatment for patients with low- to moderately
severe CAP.
Since causative microorganisms are not extensively
looked for, nor covered by antibiotic treatment in pa-
tients with CAP, it would be useful to identify specific
circumstances associated with an increased risk for these
pathogens as causative agent in CAP. Presence of such
characteristics in a patient can then be used to deter-
mine optimal treatment. It has been shown that clinical
examination, simple laboratory tests and radiographic
characteristics cannot distinguish between typical and atyp-
ical microorganisms [18–20]. However, to our knowledge
there is no scientific literature about seasons as risk factor
for atypical pneumonias as a group. In this study, we inves-
tigated whether atypical causative microorganisms in pa-
tients with CAP are more prominent during a particular
season or associated with specific patient characteristics.
Methods
Study design
A data-analysis was performed on databases from four
prospective studies [21–24]. All studies included patients
aged 18 years or older who were hospitalised with CAP
in the Netherlands and gave written informed consent.
Two studies were performed in the St. Antonius Hospital
in Nieuwegein, from October 2004 to August 2006 [23]
and from November 2007 to September 2010 [21]. The
other studies were performed in Medical Center Alkmaar
from December 1998 to November 2000 [24] and August
2005 to July 2008 [22]. On all patients, extensive micro-
biological investigations for pathogen identification was
performed such as blood cultures, sputum cultures, urine
antigen tests for L. pneumophila serogroup 1 and S. pneu-
moniae, and paired complement fixation test [21] or
ELISA test [22–24] for M. pneumoniae, C. burnetii, Chla-
mydia species and the viruses adenovirus, influenza virus
A and B, parainfluenza virus 1, 2 and 3, and the respira-
tory syncytial virus. A four‐fold increase in antibody titre
was considered as positive. Two studies performed poly-
merase chain reaction (PCR) for atypical pathogens and
respiratory viruses [21, 23]. Further details are described
elsewhere [21–24].
The following data were used from these datasets: date
of admission, age, gender, antibiotics treatment before
hospitalisation, duration of antibiotic therapy, presence
of COPD, smoking status, whether the patient was living
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in a nursing home, PSI at admission, mortality within
30 days and main causative pathogen.
Definition of season and outcome
Date of admission was classified to be either in the res-
piratory season (week 40 to 19; from early October to
early May) or the non-respiratory season (week 20 to 39).
This classification was chosen because we expected atypi-
cal microorganisms to be associated with non-respiratory
season, considering their known seasonal variation, and
because the format is easy to use in daily practice. Main
causative agents were grouped in three categories: 'atyp-
ical', 'other' and 'unknown'. Data-analysis was performed
using ‘atypical vs. other pathogen’ as outcome. The category
‘atypical’ consisted of Legionella species, M. pneumoniae,
Chlamydia species and C. burnetii as causative agents. The
category ‘other’ consisted of all other bacterial and viral
causative microorganisms. The category ‘unknown’ con-
sisted of patients with CAP in whom the causative agent
remained unidentified after microbiological investigation.
These unidentified cases were excluded from the primary
analysis since it is unknown whether the proportion of
atypical causative pathogens is lower, higher or equal to the
identified group.
Statistical analysis
Data management and statistical analysis were performed
using IBM SPSS Statistics for Windows, Version 22.0.
Categorical variables were summarized as percentages,
non-categorical variables were summarized as mean
(standard deviation) or median (interquartile range) as
appropriate. Differences between categories were observed
by means of Pearson’s chi-squared test for parametrical
variables, versus Kruskall-Wallis test for non-parametrical
samples.
To determine an age cut-off for further analyses, the per-
centage of atypical pathogens in patients younger and older
than all ages between 40 and 70 years old was calculated. A
cut-off point at age 60 was chosen based on these results.
Univariable logistic regression analysis was performed
for the following parameters: respiratory season, age <60,
male gender, presence of COPD and smoking. Variables
significant in univariable analysis and variables expected
to be associated with atypical causative agents were se-
lected for multivariable analysis. Potential interactions be-
tween age and presence of COPD were investigated using
interaction terms in logistic regression analysis. Smoking
was excluded from multivariable analysis due to 243
missing values.
Several sensitivity analyses were performed. In the first
sensitivity analyses viral pathogens were excluded. The
second analysis indicated all unknown pathogens as not
atypical; the third analysis indicated all unknown pathogens
as atypical. A fourth analysis excluded Legionella CAPs in
1999 and C. burnetii CAPs in 2009, based on the outbreaks
in those years of inclusion [6, 8]. Another sensitivity ana-
lysis excluded all Legionella CAPs. Also, an analysis was
performed including exclusively the two studies that per-
formed PCR to detect atypical pathogens and respiratory
viruses [21, 23]. Last, extra analyses were performed exclud-
ing patients who were treated with antibiotics before hospi-
talisation and patients with a severe CAP (PSI score V),
respectively.
Results
Aetiology and baseline characteristics
In total 980 patients were included in the analysis, in-
cluding all patients from the original four databases. Me-
dian age was 67 years (IQR 52–78) and 57.2 % was male.
These distributions did not significantly differ between
the four studies. Table 1 shows all baseline characteristics
of the included studies. In 565/980 (57.7 %) patients the
causative microorganism of CAP was identified. Atypical
microorganisms were causative pathogens in 117/980 pa-
tients (11.9 %); 35.9 % were cases with Legionella species
(42/117), 26.5 % with M. pneumoniae (31/117), 23.9 %
with C. burnetii (28/117), and 13.7 % with Chlamydia spe-
cies (16/117). Figure 1 shows the number of every atypical
pathogen per year of inclusion.
Further analyses were performed on the three aetiologic
categories (atypical, other pathogen and unknown). Base-
line characteristics of the patients in these three categories
are shown in Table 2. The variables age, COPD, smoking,
nursing home resident and severity of pneumonia (ac-
cording to PSI class) differed significantly between the
three categories.
Seasonal and age variations
Of all identified microorganisms, the percentage of atypical
pathogens was 20.7 % (117/565). Forty percent (40.4 %,
n = 57) of CAP cases during the non-respiratory season
were atypical, compared to 14.2 % (n = 60) during the
respiratory season (Fig. 2a).
For CAP in patients under 60 years of age, 33.8 %
(n = 74) was caused by an atypical pathogen, compared to
12.4 % (n = 43) for patients ≥ 60 years (Fig. 2b).
Combining seasonal effect and age, incidence of CAP
caused by atypical microorganisms during the non-
respiratory season was 67.2 % (n = 41) in patients younger
than 60 years. This percentage was 20 % in pa-
tients ≥ 60 years (n = 16, Fig. 2c and d).
Logistic regression analysis
In univariable and multivariable logistic regression ana-
lysis, non-respiratory season, age <60, and absence of
COPD were significantly associated with an atypical causa-
tive agent. No significant interaction was found between
age and COPD (p:0.61). Male gender was nearly significant
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in univariable analysis (OR 1.5, 95 % 1.00–2.33, p:0.052),
and significant in multivariable analysis (OR 1.7, 95 %
1.06–2.71). Too little patients were living in a nursing
home to include this variable in the analyses. Table 3
shows all ORs and 95 % CIs.
Sensitivity analyses
When viral pathogens were excluded from multivariate
analysis, odds ratios did not essentially change (see Table 4).
Similar results were found when all unknown patho-
gens were indicated as not atypical. When all unknown











Demographic characteristics No. No. No. No. No.
Male gender (%) 561 (57.2) 171 (56.3) 124 (61.7) 124 (58.2) 142 (54.2)
Age in years, median (IQR) 67 (52–78) 66.5 (51–79) 68 (51.5–76) 65 (51.5–80) 68 (52–78)
COPD (%) 236 (24.2) 34 (11.2) 64 (31.8) 43 (20.3) 95 (36.7)
Smoking (%) 211 (28.6) 81 (29.2) a 56 (26.8) 74 (29.5)
Nursing home resident (%) 29 (3.0) 16 (5.3) 3 (1.5) 4 (1.9) 6 (2.3)
PSI class IV or V (%) 435 (44.4) 142 (46.7) 84 (41.8) 94 (44.1) 115 (43.9)
30-Day mortality (%) 67 (6.8) 18 (5.9) 8 (4.0) 12 (5.6) 29 (11.1)
Aetiology (%)
Streptococcus pneumoniae 282 (28.8) 64 (21.1) 60 (29.9) 78 (36.6) 80 (30.5)
Haemophilus influenzae 55 (5.6) 9 (3.0) 18 (9.0) 7 (3.3) 21 (8.0)
Legionella species 42 (4.3) 12 (3.9) 8 (4.0) 8 (3.8) 14 (5.3)
Mycoplasma pneumoniae 31 (3.2) 5 (1.6) 4 (2.0) 13 (6.1) 9 (3.4)
Coxiella burnetii 28 (2.9) 27 (8.9) 1 (0.5) 0 (0) 0 (0)
Influenza A/B virus 25 (2.6) 7 (2.3) 6 (3.0) 3 (1.4) 9 (3.4)
Staphylococcus aureus 21 (2.1) 3 (1.0) 6 (3.0) 2 (0.9) 10 (3.8)
Chlamydia species 16 (1.6) 14 (4.6) 2 (1.0) 0 (0) 0 (0)
Adenovirus 6 (0.6) 1 (0.3) 1 (0.5) 2 (0.9) 2 (0.8)
Other bacteria 38 (3.9) 15 (4.9) 12 (6.0) 5 (2.3) 6 (2.3)
Other viruses 21 (2.1) 11 (3.6) 9 (4.5) 0 (0) 1 (0.4)
Unidentified 415 (42.3) 136 (44.7) 74 (36.8) 95 (44.6) 110 (42.0)
Results are given as number and percentage, unless mentioned otherwise
Abbreviations: COPD chronic obstructive pulmonary disease, ICU intensive care unit, IQR interquartile range, PSI pneumonia severity index
aIndicates all missing values
Fig. 1 Number of atypical pathogens per year of inclusion
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pathogens were indicated as atypical, the OR for non-
respiratory season remained significantly elevated, ORs
for age <60 and male gender remained elevated but be-
came non-significant. All ORs can be found in Table 4.
The sensitivity analysis excluding all Legionella cases
in 1999 and C. burnetii cases in 2009 showed similar re-
sults (see Table 5). The analyses excluding all Legionella
CAPs and the two studies that did not use PCR methods
all showed non-respiratory season and age < 60 to be
even stronger predictors for atypical CAP (see Table 5).
Excluding PSI class 5 resulted in remaining signifi-
cance for non-respiratory season, age <60 and COPD.
The OR for male gender was higher than 1 (1.5), but not
statistically significant. Non-respiratory season, age <60
and COPD all remained significant predictors for an
atypical causative agent in the analysis excluding patients









Male gender (%) 561 (57.2) 77 (65.8) 250 (55.8) 234 (56.4)
Age in years (IQR) 67 (52–78) 52 (41.5–67) 68 (54–78) 69 (55–80)*
COPD (%)a 236 (24.1) 9 (7.7) 135 (30.3) 92 (22.3)*
Smoking (%)b 211 (28.6) 38 (40.4) 93 (29.3) 80 (24.5)*
Nursing home resident (%)c 29 (3.0) 0 (0.0) 8 (1.8) 21 (5.1)*
PSI class IV or V (%) 435 (44.4) 38 (32.5) 219 (48.9) 178 (42.9)*
30-Day mortality (%) 67 (6.8) 6 (5.1) 33 (7.4) 28 (6.7)
Results are given as number (percentage) or median (interquartile range)
Abbreviations: COPD chronic obstructive pulmonary disease, ICU intensive care unit, IQR interquartile range, PSI pneumonia severity index
*Indicates a significant difference between the three groups (p-value <0.05). aIndicates four missing values, bIndicates 243 missing values, cIndicates 10 missing values
Fig. 2 Percentage of atypical pathogen. a Distribution of pathogens during the different seasons. b Distribution of pathogens related to age.
c Distribution of pathogens within season for patients < 60 years. d Distribution of pathogens within season for patients ≥ 60 years
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who were treated with antibiotics before hospitalisation.
Results from the analysis excluding respectively patients
with PSI class 5 and patients who used antibiotics before
hospitalisation can be found in Additional file 1: Table S1.
Discussion
In this analysis of 980 patients hospitalised with CAP in
whom extensive microbiological testing was performed,
we found non-respiratory season, age < 60, male gender
and absence of COPD to be associated with an atypical
microorganism as causative agent. The proportion of
CAP cases caused by atypical microorganisms was much
higher during the non-respiratory season than in respira-
tory season (40.4 % vs. 14.2 %). This proportion was even
higher in patients below 60 years in non-respiratory sea-
son (67.2 %).
To our knowledge, there is no scientific literature about
season as a risk factor for atypical pneumonias. Factors
that indicate an association with pneumonia caused by
this group of pathogens can optimize epidemiologic know-
ledge. Since none of the atypical pathogens are theoretic-
ally covered by empiric antibiotic treatment in non-severe
pneumonia, this knowledge can possibly reduce treatment
failure in this pathogen group. In literature, there is con-
troversy regarding the need to use antibiotics covering
atypical pathogens in the initial treatment of patients with
CAP. Recent studies show no differences in clinical
efficiency, nor differences in mortality between antibiotic
treatment with and without atypical coverage, meaning
that these atypical infections might resolve spontaneously
under inadequate antibiotic therapy [25–27]. Mostly, this
relates to the comparison of quinolone monotherapy with
beta-lactam monotherapy. However, these studies describe
empirical treatment of CAP, regularly without extensive
microbiological testing and therefore the causing pathogen
is often not identified [25, 26]. It is unknown if outcome
of CAPs caused by an atypical pathogen is improved if
adequate antibiotic coverage is started immediately on ad-
mission. In the CAP-START study, beta-lactam therapy
was non-inferior to beta-lactam plus macrolide, but 8.1 %
of the patients who were empirically treated with beta-
lactams did deviate from the study protocol due to the
need for atypical coverage. Overall, 38.7 % of the patients
in the beta-lactam group received atypical antibiotic cover-
age during admission [27].
For observing seasonal variations, we used the format
of calendar respiratory season vs. non-respiratory season
(from early May to early October). This format was used
because we expected the proportion of atypical microor-
ganisms to be elevated in the non-respiratory season.
Furthermore, the format non-respiratory season is easy
to use in daily practice. The use of other formats such as
astronomical seasons or influenza-epidemic could pro-
vide additional information on the epidemiology of CAP
in the Netherlands. We performed additional analyses
using these formats, showing the highest percentage of
atypical CAPs during summer and lowest incidence during
winter (data not shown). Using respiratory vs. non-
respiratory season showed highest predictive value.
The main limitation of this study is the fact that the
prevalence of atypical microorganisms could have been
over- or underestimated due to several reasons. First, it
is impossible to assess the proportion of atypical causa-
tive agents in the unidentified group. It is suggested that
the majority of unidentified CAP cases is caused by S.
pneumoniae, but it is unknown whether the proportion
of atypical causative pathogens is lower, higher or equal
to the identified group [28]. As only the distribution in
the group of identified cases is evident, data-analysis was
Table 3 Univariable and multivariable logistic regression analysis
of atypical versus other pathogens with cases with unknown
aetiology excluded
Univariable analysis Multivariable analysis
Parameter OR 95 % CI OR 95 % CI
Non-respiratory season 4.1 2.67–6.35** 4.3 2.68–6.84**
Age <60 years 3.6 2.35–5.50** 2.9 1.83–4.66**
Male gender 1.5 1.00–2.33 1.7 1.06–2.71*
COPDa 0.2 0.09–0.39** 0.2 0.12–0.52**
Smokingb 1.6 1.01–2.64* Excluded
Abbreviations: OR odds ratio, CI confidence interval, COPD chronic obstructive
pulmonary disease
*Indicates a p-value <0.05; **Indicates a p-value < 0.001
aIndicates four missing values; bIndicates 243 missing values
Table 4 Three multivariable logistic regression sensitivity analyses: 1) Excluding viral pathogens; 2) Cases with unknown aetiology
being indicated as not atypical; and 3) Cases with unknown aetiology being indicated as atypical
1) Atypical vs. other (viral cases excluded) 2) Atypical vs. other and unknown 3) Atypical and unknown vs. other
Parameter OR 95 % CI OR 95 % CI OR 95 % CI
Non-respiratory season 4.2 2.58–6.72** 3.0 1.95–4.47** 2.0 1.47–2.76**
Age <60 years 2.7 1.69–4.36** 3.0 1.97–4.59** 1.0 0.75–1.35
Male gender 1.7 1.09–2.81* 1.6 1.02–2.41* 1.2 0.91–1.56
COPDa 0.2 0.11–0.48** 0.3 0.15–0.65* 0.5 0.37–0.70**
Abbreviations: OR odds ratio, CI confidence interval, COPD chronic obstructive pulmonary disease
*Indicates a p-value <0.05; **Indicates a p-value < 0.001
aIndicates four missing values
Raeven et al. BMC Infectious Diseases  (2016) 16:299 Page 6 of 9
performed using ‘atypical vs. other proven causative agent’
as outcome, hereby excluding the unidentified cases. This
could have led to either over- or underestimation. How-
ever, the sensitivity analyses defining unidentified cases as
not atypical showed small differences. Since it is debatable
to appoint viral pathogens as main CAP causing micro-
organism, we performed an analysis excluding viral cases.
This analysis showed similar results for all used variables.
A second limitation is that all CAP severities were in-
cluded in the analysis. Treatment regimens differ world-
wide, but it is usually recommended to cover atypical
causative microorganisms in patients with severe CAP.
Because we aimed to identify patient characteristics as-
sociated with atypical causative microorganisms in all
cases of CAP, severe CAPs were not excluded from ana-
lyses. To validate our results for patients with low-to
moderately severe CAP, the extra analysis was performed
excluding patients with PSI class 5, which showed similar
results.
Third, we used data from four different studies, in
which not exactly the same microbiological tests were
performed. Two studies did not use PCR, whereas this
test is known to be more sensitive for diagnosing atypical
bacteria compared to conventional testing [29]. In the
studies that performed PCR, 17.4 % of atypical microor-
ganisms was identified with PCR alone. It is therefore pos-
sible that atypical microorganisms were underrepresented
in the studies without PCR [22, 24]. Including only the
two studies that used PCR methods showed elevated ORs
for non-respiratory season and age <60. All four studies
did perform two-fold serological testing for antibodies
against atypical microorganisms, but these tests have
shortcomings in sensitivity and specificity in diagnosing
atypical microorganisms [30]. Pneumococcal antigen test-
ing has not been consequently performed in all studies.
Antigen detection performed in non-urine specimens may
increase the diagnostic yield of pneumococcal infections,
but was performed in only two studies [22, 24, 31].
Finally, some patients had already been treated with
antibiotics before admission. Performing PCR and serology
for atypical pathogens while using only cultures for other
aetiology could have led to an overestimation of atypical
pathogens, since cultures are influenced by antibiotic pre-
treatment whereas serology and PCR are not. We per-
formed an analysis excluding all patients who were treated
with antibiotics before hospital admission, which did not
change the results.
A strength of this study is the large number of identi-
fied atypical pathogens, enabling us to identify signifi-
cant predictors for CAP caused by atypical pathogens.
Furthermore, extensive microbiological testing was per-
formed for every patient, hereby providing a detailed
impression on epidemiology of CAP. Our results are
applicable for hospitalised patients, but might be extrapo-
lated to general practice. Several studies have shown that
microbiological aetiology of CAP differs between hospital
and ambulatory setting, with a higher incidence of atypical
pathogens and respiratory viruses in mild cases of CAP in
ambulatory setting [10, 32, 33]. This suggests that for gen-
eral practitioners respiratory season, gender and age might
be adequate indicators to identify pneumonia patients in
whom microbiologic testing needs to be considered or in
whom antibiotic treatment (if required) should not be se-
lected purely on the existing first choice regimen. Further
research is needed to explore whether there are differences
in clinical outcome for patients under the age of 60 pre-
senting during non-respiratory season when treated with
antibiotics with and without immediate atypical coverage.
With regard to the results presented in this study, we
would recommend to perform extensive microbiological
testing in male patients, younger than 60 years old, who
are admitted with CAP during non-respiratory season in
order to optimise epidemiologic knowledge.
Conclusions
Atypical causative agents in CAP are associated with
respectively non-respiratory season, age <60 years,
male gender and absence of COPD. Therefore, exten-
sive microbiological testing should be considered in
patients <60 years old who are admitted with CAP from
early May to early October.
Table 5 Two multivariable logistic regression sensitivity analyses with: 1) Outbreaks excluded; 2) All Legionella cases excluded; 3) Only
two studies that used PCR methods
1) Outbreaks excluded 2) Legionella cases excluded 3) PCR based studies
OR 95 % CI OR 95 % CI OR 95 % CI
Non-respiratory season 4.2 2.38–7.30** 5.4 3.02–9.64** 8.3 4.35–15.80**
Age <60 years 4.2 2.38–7.30** 6.1 3.24–11.55** 3.7 1.93–7.06**
Male gender 1.8 1.02–3.05* 1.7 0.94–3.00 1.4 0.74–2.68
COPDa 0.2 0.08–0.54* 0.1 0.04–0.51* 0.2 0.07–0.71*
Abbreviations: OR odds ratio, CI confidence interval, COPD chronic obstructive pulmonary disease
*Indicates a p-value <0.05; **Indicates a p-value < 0.001
aIndicates four missing values
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Additional file
Additional file 1: Table S1. Extra multivariable logistic regression
analyses, excluding: 1) Pneumonia severity index class V; and 2) Patients
who were treated with antibiotics before hospitalisation. (DOC 37 kb)
Abbreviations
95 % CI, 95 % confidence interval; BTS, British Thoracic Society; C. Burnetii,
Coxiella burnetii; CAP, community-acquired pneumonia; COPD, chronic
obstructive pulmonary disease; ELISA, enzyme-linked immuno sorbent assay;
L. pneumophila, Legionella pneumophila; M. pneumoniae, Mycoplasma
pneumoniae; NICE, National Institute for Health and Care Excellence; OR, odds
ratio; PCR, polymerase chain reaction; PSI, pneumonia severity index; S.
pneumoniae, Streptococcus pneumoniae; SWAB, Dutch Working Party on
Antibiotic Policy
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